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Platelet Function Tests in Clinical Cardiology
Unfulfilled Expectations
Diana A. Gorog, MD, PHD,* Valentin Fuster, MD, PHD†‡
London, United Kingdom; New York, New York; and Madrid, Spain
This review is a critical evaluation of publications in the past decade on the usefulness of platelet function tests
(PFTs) in clinical cardiology, in aiding diagnosis, predicting risk, and monitoring therapy. The ideal PFT should:
1) detect baseline platelet hyperreactivity; 2) allow individualization of antiplatelet medication; 3) predict throm-
botic risk; and 4) predict bleeding risk. The practicalities of clinical cardiology demand rapid, accurate, and reli-
able tests that are simple to operate at the bedside and available 24 h a day, 7 days a week. Point-of-care PFTs
most widely evaluated clinically include PFA-100 and VerifyNow. None of these tests can reliably detect platelet
hyperreactivity and thus identify a prothrombotic state. Identification of antiplatelet nonresponsiveness or hypo-
responsiveness is highly test specific, and does not allow individualization of therapy. The power of PFTs in pre-
dicting thrombotic events for a given individual is variable and often modest, and alteration of antithrombotic
treatment on the basis of the results of PFTs has not been shown to alter clinical outcome. PFTs in current main-
stream use cannot reliably assess bleeding risk. These tests have been in use for over a decade, but the hopes
raised by PFTs in clinical practice remain unfulfilled. Although physiologically relevant measurement of platelet
function now is more important than ever, a critical reappraisal of available techniques in light of clinical re-
quirements is needed. The use of native blood, global stimulus instead of individual agonists, contribution of
thrombin generation by activated platelets to the test results, and establishment of a PFT therapeutic range for
each antiplatelet drug should be considered and is discussed. (J Am Coll Cardiol 2013;61:2115–29) © 2013
by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.080The interest in measuring platelet function in clinical
cardiology stems from the overwhelming evidence that
arterial thrombosis is the main cause of acute myocardial
infarction (AMI) and major adverse clinical events
(MACE) after percutaneous coronary intervention (PCI).
The observation that individuals with platelet hyperreactiv-
ity are more prone to such thrombotic events raised hopes of
identifying those at risk of acute coronary events who may
benefit from additional antiplatelet medication. After 2
decades of aspirin monotherapy, the introduction of double
and triple antiplatelet regimens has made the search for
clinically applicable platelet function tests (PFT) ever more
important. The expectation from an ideal PFT is to: 1) de-
tect platelet hyperreactivity both in the normal population
and in patients, allowing primary and secondary prevention;
2) detect individual variation in platelet reactivity in re-
sponse to fixed doses of antiplatelet medication, thereby
allowing individualization of therapy; 3) detect risk of future
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2012, accepted November 26, 2012.thrombosis; and 4) predict bleeding risk, in general and
peri-PCI.
From the early 1960s, light transmittance platelet ag-
gregometry (LTA) performed on citrated platelet-rich
plasma contributed significantly to our understanding of the
mechanism of platelet activation, aggregation, and the
antiplatelet effect of medication (Fig. 1). Although LTA
remains the gold standard, the practicalities of clinical
medicine demand rapid, accurate, and reliable tests that are
simple to operate at the bedside and are available 24 h a day,
7 days a week. From the late 1990s, emerging point-of-care
PFTs such as PFA-100 (Siemens Medical, Munich, Ger-
many) (1) and VerifyNow (Accumetrics, San Diego, Cali-
fornia) (2,3) fulfilled (at least partly) the aforementioned
criteria, allowing the clinical use of these tests. Others, such
as multiple electrode platelet aggregometry, vasodilator-
stimulated phosphoprotein (VASP) phosphorylation,
Cone-and Plate(let) assay (IMPACT-R, DANED SA,
Beersel, Belgium), and Plateletworks (Helena Laboratories,
Beaumont, Texas), are variably limited by being labor
intensive and time consuming, and require experience and
expertise to perform and evaluate; therefore, they are more
adapted to research than the point-of-care environment.
This review is a critical evaluation of publications in the
past decade on the usefulness of PFTs in clinical cardiology
in aiding diagnosis, predicting risk, and monitoring therapy.
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Platelet Function Tests in Cardiology May 28, 2013:2115–29Detecting Baseline
Platelet Hyperreactivity
(Prothrombotic Status)
and Cardiac Risk
Platelet hyperreactivity is defined
here as the enhanced response of
platelets to agonists in subjects
who are not taking antiplatelet
medication. This definition is differ-
ent from high residual platelet reac-
tivity (HRPR) despite antiplatelet
therapy, which is discussed later in
the text.
There has been a continuous
search for clinical markers that
can predict the occurrence and
risk of MACE. Although large
studies showed significant corre-
lation between elevated levels of
various plasma markers (fibrino-
gen, von Willebrand factor, fac-
tor VIII) and the occurrence of
ischemic events, because these
markers are not specific for cor-
onary disease and cannot be used
to identify individuals at risk, they
had no impact on everyday clinical
practice. Measurement of sponta-
neous aggregability of platelets in
response to shear stress (stirring)
was the first test to detect platelet
hyperreactivity. Among patients
with prior AMI, those with spon-
taneous platelet aggregation had a 3- to 5-fold increase in
MACE over a 5-year follow-up, compared with those
without spontaneous aggregation (4). Platelet hyperreac-
tivity was an independent risk factor for vascular occlu-
sion in healthy volunteers (5) and was demonstrated in
patients with acute coronary syndrome (ACS) (6), hyper-
lipidemia, hypertension, diabetes, rheumatoid arthritis,
moking, and acute exercise. Platelet hyperreactivity in
ealthy individuals was also detected by a platelet-
ounting technique, whole-blood flow cytometry, and by
latelet aggregometry using submaximal concentrations
f epinephrine (7,8). However, these laboratory tests lack
tandardization, definitions of clear-cut “normal” and
hyperreactive” ranges, and are not suitable for identify-
ng individual patients at risk (Table 1).
llowing Individualization
f Antiplatelet Medication
n response to reports on “aspirin resistance,” PFTs were
sed to detect and monitor sensitivity to antiplatelet med-
Abbreviations
and Acronyms
AA  arachidonic acid
ACS  acute coronary
syndrome(s)
ADP  adenosine
diphosphate
AMI  acute myocardial
infarction
CYP  cytochrome P-450
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
HR  hazard ratio
HRPR  high residual
platelet reactivity
LTA  light transmittance
platelet aggregometry
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
PFT  platelet function
test
PRI  platelet reactivity
index
PRU  P2Y12 reactivity
unit(s)
ST  stent thrombosis
TXB2  thromboxane B2
VASP  vasodilator-
stimulated phosphoproteincation. To reduce the large interindividual variability ob- berved with PFTs, newer point-of-care tests substantially
ncreased the concentration of agonist. Although platelet
yperreactivity can only be observed at very low agonist
oncentrations, point-of-care PFTs employ agonists at
uch higher concentrations. As such, interindividual
ariability in platelet response to antiplatelet medication
s reduced considerably, but the ability to detect sponta-
eous platelet hyperreactivity in an individual subject is
ost.
Although aspirin was the only effective antiplatelet agent
vailable, monitoring was not required. Inhibition of cyclo-
xygenase-1 was regarded as the sole mechanism of the
ntiplatelet effect of aspirin. Because aspirin 75 mg daily
nhibits thromboxane A2 formation by 90%, a dose of 75
o 150 mg daily was considered universally effective, and
ustified the “one dose for all” policy. Early reports of aspirin
esistance, namely the reduced or absent inhibition of
gonist-induced platelet aggregation, gave impetus to using
oint-of-care tests for monitoring therapy. Depending on
he agonist and cutoff level selected, 5% to 60% of patients
ere termed “aspirin-resistant.” Findings of resistance, de-
pite nearly complete inhibition of arachidonic acid (AA)-
nduced aggregation, coupled with the observed dose de-
endence of resistance, suggested that aspirin may exert
ntiplatelet effects through non–cyclo-oxygenase-1 path-
ays (9). The antiplatelet effect of aspirin was limited in
hole blood with normal calcium levels, and the adminis-
ration of high-dose aspirin for 7 days (cumulative dose 960
g) was associated with considerable recovery of AA-
nduced platelet aggregation (10). Although tests that em-
loy AA-induced aggregation showed good agreement in
he prevalence of aspirin resistance (0% to 6%) (9), this did
ot correlate well with non–AA-dependent assays (9), and
urthermore, a comparison of 6 PFTs showed poor agree-
ent between tests in detecting prevalence of aspirin resis-
ance: 10.3% to 51.7% for aggregometry using adenosine
iphosphate (ADP), 18.0% for whole-blood aggregometry,
9.5% for PFA-100, 6.7% for VerifyNow, and 22.9% for
rinary thromboxane B2 (TXB2) concentration (11).
greement was also poor when tests were compared with
A-induced LTA. One study found serum TXB2 a useful
easure of aspirin nonresponsiveness (12), but another
howed that urinary and serum TXB2 did not correlate with
ther PFTs (13,14). A growing list of publications demon-
trated that PFA-100 was not capable of measuring aspirin
esistance (15). These findings cast doubt on the reliability
nd usefulness of PFTs in correctly classifying patients as
spirin resistant, leading some to suggest that “the term
aspirin resistance’ based on inadequate knowledge of im-
erfect laboratory tests does a disservice to physicians and
atients” (16).
The impressive reduction in MACE when thienopyri-
ines were added to aspirin began the era of dual antiplatelet
herapy (DAPT), with ticlopidine rapidly overtaken by
lopidogrel, following the recognition of potentially fatal
one marrow suppression by ticlopidine. Studies reported
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May 28, 2013:2115–29 Platelet Function Tests in Cardiologythat 4% to 30% of patients exhibited “clopidogrel resistance”
(17), some 5% to 6% exhibited DAPT resistance (18,19),
and 1 study reported no subject to be unresponsive to both
aspirin and clopidogrel, regardless of the assay used (20).
Comparison of 3 PFTs (LTA, VASP, and VerifyNow)
showed the prevalence of clopidogrel nonresponsiveness to
be 13%, 39%, and 33%, respectively, with poor agreement
between assays (11,21) although P2Y12 receptor–specific
tests, such as VASP and VerifyNow P2Y12, appear to
correlate strongly with one another (22). The VASP-assay is
considered the reference standard for assessing P2Y12 an-
agonist therapy. Although some suggested the VASP assay
o be the ideal PFT for monitoring clopidogrel responsive-
ess (23), in patients on clopidogrel, the VASP index did
ot correlate well with P2Y12 receptor occupancy (24). The
one-and-Plate(let) analyzer (IMPACT-R ADP test) was
ound to be unsuitable for monitoring the clopidogrel effect
25). When LTA, whole-blood aggregometry, PFA-100,
nd VerifyNow were compared, none could reliably distin-
uish between patients who had, or had not, ingested
lopidogrel (26), although this study defined clopidogrel
yporesponsiveness as 50% inhibition of baseline platelet
ggregation, based on contemporaneous American College
f Cardiology/American Heart Association/Society Cardio-
Figure 1 Schematic Depicting Platelet Activation and Site of A
The main pathways for platelet activation, including arachidonic acid (AA), adenosi
(GP) Ib and IIb/IIIa, are depicted. These pathways have complex interactions, and
bosis based on the clinical setting. It is therefore very difficult to assess the overa
the response to a specific drug.ascular Angiography and Interventions guidelines, whereas mn-treatment platelet reactivity is now regarded to be a
etter measure of thrombotic risk (27).
Thus, identification of clopidogrel nonresponsiveness is
est specific, and additionally, clopidogrel’s variable anti-
latelet effect means that PFTs are also unsuitable for
iagnosing drug noncompliance. Correlation between tests
as, at best, modest; these assays are therefore not inter-
hangeable (28). Whether individualization of clopidogrel
reatment based on PFT results is necessary is questionable,
iven that clinical studies have shown clopidogrel benefit in
rials where PFT was not performed. In the setting of PCI
n the CURE (Clopidogrel in Unstable Angina to Prevent
ecurrent Ischemic Events) trial (29) and STEMI in
OMMIT (Clopidogrel and Metoprolol in Myocardial
nfarction Trial) (30), clopidogrel significantly reduced
ACE (30), without testing for or tailoring treatment to
lopidogrel nonresponsiveness. Thus, whether individual-
zation of clopidogrel treatment based on PFT results is
ecessary could be questioned, given that clinical studies
ave shown clopidogrel benefit in trials where PFT was not
erformed. However, whether the magnitude of benefit was
reatest in those who were “responders” to clopidogrel is
nknown, and if this were demonstrated to be true in future
tudies, it may support PFT-guided treatment. Further-
of Commonly Used Antithrombotic Agents
hosphate (ADP), von Willebrand factor (vWf), PAR-1, and surface glycoproteins
thways in an individual may vary in the magnitude of their contribution to throm-
elet reactivity by using only a single pathway of platelet activation and measuringction
ne dip
the pa
ll platore, although VASP and multiple electrode platelet ag-
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Platelet Function Tests in Cardiology May 28, 2013:2115–29gregometry recorded a significant reduction of the number
of clopidogrel-resistant patients after doubling the dosage of
clopidogrel (31), this maneuver appears not to reduce the
incidence of MACE in comparison with standard dosage
(32,33).
Initially, small studies suggested that individualization of
antiplatelet therapy based on the results of PFT may reduce
MACE. In a randomized study of 162 patients, VASP-
guided optimization of platelet reactivity in those demon-
strating clopidogrel resistance (VASP index 50%), with
repeated clopidogrel loading pre-PCI, reduced 30-day
MACE, compared with conventional, non–PFT-tailored
care (34). The same group showed that in 429 patients
undergoing PCI, VASP-guided clopidogrel treatment in
those with a VASP index 50%, reduced stent thrombosis
ST) (0.5% vs. 4.2%, p  0.01) and MACE (0.5% vs. 8.9%,
 0.001) compared with standard care (35). In 263
atients demonstrating resistance to aspirin, clopidogrel or
oth as detected by VerifyNow, randomized to receive
irofiban or placebo in addition to DAPT before PCI,
irofiban significantly reduced periprocedural AMI and
dverse events at 30 days (36). In the much larger GRAVITAS
Gauging Responsiveness With a VerifyNow Assay–Impact
PFTs in Clinical CardiologyTable 1 PFTs in Clinical Cardiology
Test Advantages
Detecting platelet hyperreactivity Platelet hyperreactivity associated with i
MACE in population studies
Detecting HRPR PFTs identify reduced or absent inhibitio
agonist-induced platelet aggregation
(antiplatelet “resistance”)
HRPR on aspirin and clopidogrel widely s
with many PFTs
High agonist concentrations in PFTs redu
individual variability in platelet respon
antiplatelet medication
Predicting adverse cardiovascular
events
Definite correlation between HRPR and r
MACE and ST
Predicting bleeding risk Enhanced platelet response associated w
increased bleeding risk
HRPR  high residual platelet reactivity; MACE  major adverse cardiac event(s); PFT  plateletn Thrombosis and Safety) trial, of 5,429 patients on hAPT undergoing PCI, 2,214 patients with HRPR on
erifyNow P2Y12 assay were randomized to clopidogrel 75
r 150 mg daily for 6 months. High-dose clopidogrel
chieved a 22% reduction in HRPR, but failed to reduce
ardiovascular death, AMI, or ST (32). These results do not
upport the application of VerifyNow P2Y12 assay to guide
ntiplatelet therapy (37).
The poor correlation between different PFTs is not
ecessarily a barrier to clinical adoption of any single test,
ecause the tests assess different aspects of platelet function.
FTs that are most P2Y12 receptor specific, such as VASP
nd VerifyNow P2Y12, correlate strongly with one another
nd with levels of clopidogrel’s active metabolite (22).
owever, a weak correlation was observed between VASP
nd LTA ADP assay (28), perhaps because platelet aggre-
ation induced by 2 mol/l ADP was particularly sensitive
o low levels of receptor blockade, whereas the VASP
equired 60% receptor blockade to achieve substantial
nhibition (38). There are many different PFTs available,
nd although VerifyNow is the dominant point-of-care
FT in clinical use, none stand out as superior to the others
or guiding antiplatelet therapy, because large-scale clinical
rials to address their clinical usefulness in tailoring therapy
Limitations
e Platelet hyperreactivity not specific for cardiovascular disease and also
detectable in many disease states
High agonist concentrations in PFT reduce ability to detect spontaneous
platelet hyperreactivity
Lack of standardization between tests
No clear-cut definition of normal and abnormal ranges
Incidence of “resistance” varies with agonist and cutoff level used
Incidence and meaning of HRPR on newer antiplatelet agents (e.g.,
ticagrelor, prasugrel, thrombin antagonists) not widely studied
Alteration in antiplatelet medication to reduce HRPR does not reduce
cardiovascular events
High agonist concentrations reduce ability to detect spontaneous
platelet hyperreactivity
Poor correlation between results of various PFTs
Great variability in definition of resistance
Unsuitable for diagnosing noncompliance
At low plasma calcium levels in citrated blood in PFT, platelets do not
generate thrombin; thus, current PFTs are unlikely to be suitable for
monitoring thrombin antagonists
No correlation between improved HRPR and reduction in events
Large variation in level of risk reported between different clinical trials,
different PFTs, different antiplatelet regimens and different clinical
conditions
Individualization of antiplatelet therapy based on PFTs results cannot
be recommended
Meaning of HRPR with more than 1 agonist unknown
No test accurately predicts bleeding risk for a given individual
Thrombin is key player in hemostasis, but its contribution to hemostasis
cannot be assessed in citrated blood used in PFT
No clear-cut definition of level of platelet response that increases
bleeding risk
No evidence that alteration of antiplatelet therapy based on PFT results
reduces bleeding
n test; ST  stent thrombosis.ncreas
n of
tudied
ce
se to
isk of
ithave not been performed.
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There is overwhelming evidence of a correlation between
reduced responsiveness to antiplatelet therapy (based on
PFTs) and MACE (Table 2) (39–41). However, among
reports, there is great variability in the definition of resis-
tance, even between studies using the same technique. Some
patients classified as nonresponders by one PFT were
considered responders by another, and often, baseline dif-
ferences were discounted. Although HRPR is frequent
(30% to 40% for clopidogrel), the low frequency of MACE
following PCI (0.5% to 2.5%) means that randomized
studies need to have a sufficiently large sample size to
demonstrate a relationship between PFT and events. Here,
we focus on data obtained in patients tested with the most
frequently used assays, PFA-100 and VerifyNow.
There is a wide range in the predictive power of PFTs for
cardiovascular events. The PFA-100 showed no significant
difference in MACE between aspirin responders and non-
responders (42–44). Low platelet responsiveness predicted a
variable risk of coronary events, from hazard ratio (HR): 36
(45) to HR: 3 (46), a variation greater than that attributable
simply to study population differences. In a head-to-head
comparison in 1,069 PCI patients, the predictive power
(area under the curve) of LTA, VerifyNow, and Platelet-
works was modest (0.63, 0.62, and 0.61, respectively),
whereas IMPACT-R and the PFA-100 assays were unable
to discriminate between patients with and without MACE
at 1 year (43). The PFA-100 does not appear useful for
detection of clopidogrel effect (47). In 144 patients, VASP
PRI detected all 21 low-risk MACE with a negative
predictive value of 100% (48). However, in a small Swedish
study, VASP assay results were not related to the occurrence
of ST or AMI (49). Although studies have shown that low
responders to ADP receptor antagonists, identified using
VASP, have higher MACE events post-PCI (48,50–52),
with a similar cut-point for clopidogrel and prasugrel
(platelet reactivity index [PRI] 50%), others showed that
VASP results failed to predict ST following drug-eluting
stent (DES) implantation (53) and did not differ between
patients with angiographically confirmed ST or AMI, and
controls (49). In 222 patients undergoing PCI hyporespon-
siveness to clopidogrel as detected with VerifyNow was able
to predict 30-day MACE (area under the curve 0.649, p 
0.032) (54). In 683 post-PCI patients, VerifyNow P2Y12
assay was able to predict cardiovascular death/nonfatal AMI
(HR: 2.55 and 3.36; p  0.034/0.004, respectively) (55). In
,789 ACS patients undergoing PCI, HRPR detected by
TA (ADP) occurred in 14% and was related to MACE
41). However, a recent study of 2,849 patients tested
ost-PCI with the VerifyNow P2Y12 assay showed no
ifference at 2 years in the occurrence of MACE between
atients with and without HRPR (56). In 771 stable CAD
atients, antiplatelet resistance, measured with specific or
ggregation-based assays, added no incremental predictive
alue for MACE, over and above established risk factors57). Of 1,226 Korean patients, in those undergoing PCI
or AMI, HRPR with the VerifyNow P2Y12 assay was
elated to 1-year cardiovascular events, whereas in stable
CI patients, HRPR conferred no prognostic significance
58). In 186 patients receiving DES, there was no difference
n the 1-year clinical event rate between those who were and
ere not classified as low responders to aspirin or to
lopidogrel with VerifyNow (59). In 378 patients undergo-
ng PCI, the results of VerifyNow P2Y12 had no prognostic
alue in predicting adverse cardiovascular events at 6
onths (60).
In a recent meta-analysis of 6 studies involving 3,000
atients undergoing PCI, enhanced platelet reactivity de-
ected by VerifyNow P2Y12 assay was associated with
ACE, and the level of platelet reactivity was directly
elated to risk (39). The practical value of testing patients
or “clopidogrel resistance” is best shown by the outcome of
he GRAVITAS and ADAPT-DES (Assessment of Dual
ntiplatelet Therapy with Drug-Eluting Stents) studies. In
RAVITAS, 2,796 patients were tested with VerifyNow
2Y12 post-PCI (61). Low on-treatment platelet reactivity
208 P2Y12 reactivity units [PRU]) was an independent
predictor of reduced MACE at 60 days (HR: 0.23; 95%
confidence interval: 0.05 to 0.98; p  0.047) but only
tended to be associated with improved outcome at 6
months. In 2,000 post-PCI patients with HRPR with
VerifyNow (defined as 230 PRU), high-dose clopidogrel
failed to reduce MACE, compared with standard-dose
clopidogrel (32).
In ADAPT-DES, 8,575 patients undergoing PCI with
DES were tested with VerifyNow (62). At 30 days, the rate
of probable or definite ST was 0.46%, and was related to the
level of platelet inhibition in response to ADP antagonists,
but not related to the baseline level of platelet P2Y12
response, aspirin, or overall platelet responsiveness after
DAPT loading. The modest sensitivity, specificity, and poor
prognostic utility of such testing, coupled with the low
prevalence of events, indicated that testing for ADP antag-
onist responsiveness was unlikely to provide useful informa-
tion to guide clinical decision making. These results indicate
that for individuals, point-of-care PFTs provide no more
information on MACE than C-reactive protein levels (56),
ematocrit (63), mean platelet volume (64), or routine
ematologic tests (65). However, 2 recent, albeit much
maller studies, showed promise for PFT. In the CILON-T
Efficacy of CILostazol ON Ischemic Complications After
ES Implantation) trial, 716 patients undergoing PCI were
nalyzed with VerifyNow P2Y12 (PRU) and aspirin reac-
ivity unit assays. At 6 months, neither PRU nor aspirin
eactivity unit data on their own had predictive power, but
he combined aspirin reactivity unit and PRU result was a
ignificant predictor of MACE (HR: 6.34, p  0.021) (66).
In 1,000 ACS patients undergoing PCI, HRPR to more
than 1 agonist (ADP, AA, and collagen) was strongly
predictive of MACE (odds ratio: 4.7; p  0.0001), whereas
isolated platelet hyperreactivity to a single agonist had no
Trials of PFT and Adverse Cardiovascular EventsTable 2 Trials of PFT and Adverse Cardiovascular Events
First Author,
Year (Ref. #)
Trial Name Test Used Condition Evaluated N Trial Design Intervention Follow-Up Outcome Assessed Results
Brar et al.,
2011 (39)
VerifyNow Patients undergoing PCI
on DAPT
3,059 Meta-analysis
PRU 230 vs. PRU 230
At least 1
month
MACE (death, AMI,
or ST)
15% vs.7 % (p  0.0001)
Breet et al.,
2010 (43)
LTA, VerifyNow, Plateletworks
and IMPACT-R and PFA-
100
Elective PCI on DAPT 1,069 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
12 months Death, AMI, ST,
ischemic CVA
LTA: 12% vs. 6% (p  0.001);
VerifyNow 13% vs. 6%
(p  0.001); Plateletworks
13% vs. 6% (p  0.005);
IMPACT-R (p  NS) and
PFA-100 (p  NS)
Marcucci et al.,
2009 (55)
VerifyNow ACS undergoing PCI
with DES or BMS on
DAPT
683 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
12 months CV death, AMI 17% vs. 12% (p  0.11)
Campo et al.,
2006 (40)
LTA and PFA-100 STEMI and stable CAD
on DAPT
70 STEMI and 30
stable CAD
Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
12 months Death, AMI, TVR PFA-100 HR: 11, p  0.02;
LTA HR: 5.2 p  0.03
Modica et al.,
2009 (44)
PFA-100 and Aggregometry AMI on DAPT 334 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
44 months Death, AMI, or
stroke
p  NS
Gianetti et al.,
2006 (45)
PFA-100 Stable or ACS patients
undergoing PCI on
DAPT
175 Prospective observational
study assessing ASA
or clopidogrel
resistance
6 months MACE (CV death,
AMI, or TVR)
ASA resistance HR: 8.5,
p  0.004; clopidogrel
resistance HR: 23,
p  0.003
Bonello et al.,
2007 (48)
VASP Stable or NSTEMI
patients undergoing
PCI on DAPT
144 Prospective observational
study
HRPR vs. normal platelet
reactivity
6 months MACE (CV death,
AMI, ischemic
stroke, or
revascularization)
21% vs. 0% (p  0.01)
Varenhorst et al.,
2011 (49)
VASP and VerifyNow ST or AMI in patients
6 months of prior
PCI on DAPT
78 Retrospective case
control
ST or AMI VerifyNow PRU higher in ST
patients than controls
(p  0.001); VASP: no
difference (p  NS)
Bonello et al.,
2011 (51),
2012 (52)
VASP PCI for ACS receiving
prasugrel as part of
DAPT
310 Prospective observational
study of HRPR vs.
normal platelet
reactivity
30 days MACE (CV death,
AMI, ST)
9% vs.0.4 % (p  0.001)
1 year 22% vs. 3% (p  0.001)
Ko et al.,
2011 (54)
VerifyNow and MEA Patients undergoing PCI
on DAPT
222 Prospective observational
study
30 days MACE (CV death,
AMI, stroke, or
revascularization)
VerifyNow P2Y12 (but not
MEA) predictive of
periprocedural MI
(p  0.02) and 30-day
MACE (p  0.03)
Continued on the next page
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First Author,
Year (Ref. #)
Trial Name Test Used Condition Evaluated N Trial Design Intervention Follow-Up Outcome Assessed Results
Reny et al.,
2012 (57)
ADRIE
PFA-100 C/Epi and VASP-PRI Stable CAD on DAPT 771 Prospective observational
study comparing
HRPR to at least 1
antiplatelet agent vs.
normal platelet
reactivity
3 years MACE (CV death,
AMI, UA,
revascularization,
ischemic limb, or
ischemic CVA)
16% vs. 15% (p  0.71)
Ahn et al.,
2012 (58)
VerifyNow Undergoing PCI for AMI
or stable CAD on
DAPT
1,226 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
1 year MACE (CV death,
AMI, ST)
For AMI group: 9% vs. 0.4%
(p  0.001)
For non-AMI group: 7% vs. 8%
(p  0.193)
Yu et al.,
2012 (59)
VerifyNow Undergoing PCI with
DES on DAPT
186 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
1 year MACE (CV death,
AMI, ST, and
stroke)
6% vs. 13% (p  0.99)
Paulu et al.,
2012 (60)
VerifyNow Undergoing PCI on
DAPT
378 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
6 months MACE (death, AMI,
stroke)
No difference in platelet
reactivity between patients
with and without events;
OR: 1.0 (p  0.9)
Park et al.,
2011 (56)
VerifyNow Undergoing PCI with
DES on DAPT
2,849 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
2.2 years MACE (death, AMI,
ST, stroke)
2.8% vs. 2.4% (p  0.18)
Kirtane et al.,
2012 (69)
ADAPT-DES
VerifyNow Undergoing PCI with
DES on DAPT
8,575 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
30 days ST HRPR associated with ST,
especially in ACS patients
(p  0.0001)
Substantial overlap in PFT
results between patients
who had and who had not
had ST
Lee 2011 (66)
CILON-T
VerifyNow Undergoing PCI with
DES on DAPT
716 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
6 months MACE (CV death,
AMI, stroke)
HRPR (combined ASA 
clopidogrel resistance)
predictive of MACE
(HR: 6.3, p  0.02)
Neither ASA nor clopidogrel
resistance alone predicted
MACE
Marcucci et al.,
2010 (67)
LTA ACS patients
undergoing PCI on
DAPT
1,108 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
12 months CV death and AMI HRPR to more than 1 agonist
predicted AMI and death
(p  0.0001)
Isolated platelet
hyperreactivity to only 1
agonist had no predictive
value
Mangiacapra
et al.,
2012 (68)
ARMYDA-PROVE
VerifyNow Elective PCI on DAPT 732 Prospective observational
study comparing
HRPR vs. normal
platelet reactivity
30 days Ischemic events
(death, AMI, or
TVR) and
bleeding events
15% vs. 8% (p  0.005)
Continued on the next page
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Trenk et al.,
2012 (115)
TRIGGER-PCI
VerifyNow Stable CAD undergoing
PCI with DES and
HRPR on DAPT
212 Prospective randomized
trial
Prasugrel vs. clopidogrel 6 months CV death or AMI 0% vs. 1% (prasugrel vs.
clopidogrel) p  NS
Greater platelet inhibition
with prasugrel vs.
clopidogrel
Price et al.,
2011 (32)
GRAVITAS
VerifyNow Patients with HRPR
within 12-24h of PCI
with DES on DAPT
2,214 Prospective, randomized
double blind
High-dose (150 mg) vs.
low-dose (75 mg)
clopidogrel
6 months MACE (CV death,
AMI, ST)
2.3% vs. 2.3%
(p  0.97)
Bonello et al.,
2008 (34)
VASP Patients with HRPR
receiving DES on
DAPT
162 Prospective, randomized
open-label
Clopidogrel dose
adjusted to obtain
VASP 50% vs.
standard care
1 month MACE (CV death,
ACS, ST,
revascularization)
0% vs. 10% (p  0.007)
Bonello et al.,
2009 (35)
VASP Patients with HRPR
receiving DES on
DAPT
429 Prospective, randomized,
open-label
Clopidogrel dose
adjusted to obtain
VASP 50% vs.
standard care
1 month ST 0.5% vs. 4.2% (p  0.01)
Vaglimigli et al.,
2009 (36)
3T/2R
VerifyNow Elective PCI; resistant to
ASA, clopidogrel, or
both; on DAPT
263 Prospective, randomized,
double-blind
Tirofiban or placebo, in
addition to DAPT
1 month Troponin elevation
3 ULN
20% vs. 35% (p  0.009)
Parodi et al.,
2011 (41)
LTA ACS undergoing PCI on
DAPT
1,789 Prospective open-label
interventional trial
Patients with HRPR had
clopidogrel dose
increased or
switched to
ticlopidine
2 years CV death, AMI,
urgent
revascularization,
or stroke
15% vs. 9% (p  0.003)
ACS  acute coronary syndrome(s); AMI  acute myocardial infarction; ASA  acetyl salicylic acid; CAD  coronary artery disease; CV  cardiovascular; CVA  cerebrovascular accident; DAPT  dual antiplatelet therapy; DES  drug-eluting stent; HR  hazard ratio; LTA
 light transmittance aggregometry; MEA multiple electrode platelet aggregometry; NSTEMI  non–ST-segment elevation myocardial infarction; OR  odds ratio; PCI percutaneous coronary intervention; PRU platelet reactivity unit(s); STEMI  ST-segment elevation
myocardial infarction; TVR  target vessel revascularization; UA  unstable angina; ULN  upper limit of normal; VASP  vasodilator-stimulated phosphoprotein; other abbreviations as in Table 1.
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shortcoming of all point-of-care PFTs of using different
agonists in separate cartridges to assess different platelet
receptor antagonists. In order to monitor dual or triple
antiplatelet therapy and perhaps the novel oral thrombin
antagonists, platelet response to 4 agonists (ADP, AA,
collagen, and thrombin) should be measured simultane-
ously. Whether the increased costs of measuring response to
multiple stimuli will be justified by the benefit of improved
risk assessment, remains to be seen.
Recently, cut values have been proposed for on-treatment
platelet reactivity for PFTs that predict MACE predomi-
nantly in the setting of PCI, based on receiver-operating
characteristic curve analysis (27). Several studies have de-
fined the cut-point for risk, when using the VerifyNow
(PRU above 208 to 235) (39,68), or VASP (50% to 53%)
(48,50,51). The level of on-treatment platelet reactivity is
proposed to be a better measure of thrombotic risk than
responsiveness to clopidogrel. HRPR was defined as: 1) PRI
50% by VASP-P analysis; 2) 235 to 240 PRU using
VerifyNow; 3) 46% maximal 5-mol/l ADP-induced
aggregation; and 4)468 arbitrary aggregation units/min in
response to ADP by Multiplate analyzer (Roche, Basel,
Switzerland). The net reclassification index, a measure of
incremental prognostic value (see the following text), using
the VerifyNow P2Y12 assay in the meta-analysis of post-
PCI patients, was 23% (39), and in ADAPT-DES, the net
reclassification index was 28.7% for PRU 208, leading to
reclassification of almost one-third of patients (69). How-
ever, there are no large-scale clinical studies demonstrating
that adjustment of antiplatelet therapy based on any of these
improves clinical outcome.
Influence of Genetic Variability on PFT
Clopidogrel is transformed into its active metabolite by
cytochrome P-450 (CYP) enzymes. Genetic polymorphism
exists for CYP2C19 expression. Depending on ethnicity,
30% to 55% of persons harbor a loss of function of the
CYP2C19 allele (CYP2C19*2). Compared with noncarriers,
CYP2C19*2 carriers treated with clopidogrel had lower
levels of active clopidogrel metabolite; HRPR as assessed
using LTA (70) and VASP (71); and a higher rate of
MACE, including ST (70). HRPR, detected by VASP and
VerifyNow, could be overcome by tripling the maintenance
dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozy-
gotes, but not in homozygotes (72), although repeated
boluses of clopidogrel 600 mg did overcome the HRPR in
the majority of patients (73). Prasugrel appears more effec-
tive than high-dose clopidogrel in overcoming HRPR in
CYP2C19*2 carriers (74). In the GIFT (Genotype Informa-
tion and Functional Testing) study, the genetic substudy of
GRAVITAS, blood samples were tested for 40 polymor-
phisms, and these correlated with the results of on-
treatment VerifyNow P2Y12 assay. HRPR was increased
11-fold in homozygotes and increased 62% in heterozygotesfor the CYP2C19*2 gene, compared with noncarriers. The
study did not find any association of the CYP2C19*17
gain-of-function gene with reduced on-treatment platelet
reactivity (75).
Polymorphism also exists in paraoxonase 1 (PON1), a
crucial enzyme responsible for clopidogrel bioactivation
(76), but studies have failed to confirm an association
between PON1 polymorphism and on-clopidogrel platelet
reactivity using VerifyNow (75,77–80).
The results of meta-analyses are conflicting. A report on
9 studies in 9,685 patients undergoing PCI (81) and another
involving 10 studies in 11,959 patients (82), both concluded
that reduced-function CYP2C19 alleles expose patients
treated with clopidogrel to increased risk of cardiovascular
events. However, 2 recent meta-analyses (not confined to
stented patients) showed that although there was an asso-
ciation between CYP2C19 genotype and clopidogrel re-
sponsiveness, genotype was not associated with cardiovas-
cular events, with the possible exception of ST in the
subgroup of patients undergoing PCI, where ST was asso-
ciated with CYP2C19 loss-of-function alleles (83,84).
Predicting Bleeding Risk
Because there is a fine line between platelet inhibition and
bleeding risk, these 2 factors must be carefully balanced, and
any test that could assist the clinician would be highly
desirable. Although aspirin is a mild platelet inhibitor, its
advantage is the relatively low incidence of bleeding. Clopi-
dogrel reduces AMI but at a cost of increased bleeding (85).
In 17,383 patients undergoing PCI, triple therapy (glyco-
protein IIb/IIIa receptor antagonist, aspirin, clopidogrel,
and/or cilostazol) was associated with an 80% increase in
blood transfusions and an 8-fold increase in thrombocyto-
penia, compared with aspirin monotherapy (86). In patients
undergoing PCI, enhanced clopidogrel responsiveness car-
ried an increased risk of major bleeding (87–89). Campo et
al. (90) tested 300 patients post-PCI using VerifyNow, and
showed that on-treatment platelet reactivity was predictive
of bleeding events, and they identified a safety range for
platelet reactivity, outside of which thrombotic or bleeding
risk is increased. In 2,500 patients undergoing PCI, bleed-
ing was twice as common in those with enhanced platelet
response to ADP than in normal respondents (88). In some
500 ACS patients, clopidogrel hyperresponder status as
measured with LTA and VASP was associated with major
bleeding events over 30 days (91,92). Furthermore, very low
VerifyNow PRU values, within the bleeding range, have
been documented in clopidogrel-resistant patients switched
to ticagrelor (93). VASP index was measured in 301 ACS
patients post-PCI, treated with prasugrel. A cut value of
PRI 16% was predictive of bleeding events at 1 year (52).
The POPular (Do Point-of-Care Platelet Function Assays
Predict Clinical Outcomes in Clopidogrel Pretreated Pa-
tients Undergoing Elective PCI) study assessed the value of
clopidogrel-induced platelet inhibition in predicting bleed-
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Platelet Function Tests in Cardiology May 28, 2013:2115–29ing risk in the setting of PCI, using 5 different tests (LTA,
VerifyNow, Plateletworks, IMPACT-R, and PFA-100).
None of the tests predicted bleeding complications (10).
In patients undergoing PCI (n  2,533), ADP-induced
latelet aggregation was assessed by VerifyNow P2Y12
ssay after 600-mg clopidogrel loading. The primary efficacy
ndpoint was the 30-day incidence of definite or probable
T, and the primary safety endpoint was the occurrence of
ajor bleeding. Analyses of cutoff values derived from
eceiver-operating characteristic curves revealed the exis-
ence of a “therapeutic window” for P2Y12 receptor inhibi-
ion, within which sufficient antiplatelet effect could be
chieved without increased bleeding (94). The safety
hreshold of PFTs could be determined with the skin
leeding time test. In a recent study, bleeding episodes in
atients on DAPT were significantly associated with the
latelet response to ADP 2mol/l, but not in response to 4
r 8 mol/l (95).
In addition to double and triple antiplatelet medication,
ovel oral thrombin antagonists and platelet thrombin
eceptor inhibitors will soon be added to the present
rmamentarium. The need to identify patients at risk of
leeding is much greater for oral thrombin inhibitors than
or aspirin/clopidogrel treatment. Although it is claimed
hat the predictable pharmacokinetics makes monitoring of
hrombin inhibition dispensable, this is unlikely to be the
ase. Because the local thrombin-generating capacity of
latelets shows high individual variation (96), fixed-dose
hrombin antagonist treatment would mandate monitoring
o reduce bleeding. A PFT providing both the optimal
ange of platelet reactivity necessary to prevent thrombotic
vents, as well as the range to avoid excessive bleeding,
ould therefore be highly desirable (97).
ossibilities to Improve
linical Usefulness of PFTs
ecause PFTs are not particularly useful in everyday clinical
ractice, a critical reappraisal of these tests is needed. We
ropose the following to potentially improve the clinical
elevance and usefulness of PFTs.
. Use of native, instead of citrate-anticoagulated blood:
All PFTs presently in clinical use employ citrate-
anticoagulated blood at very low plasma calcium ion
concentration. Such an unphysiological environment dis-
torts the response of platelets to various agonists (17).
The difference in citrate concentrations (3.2% or 3.8%)
has significant influence on the results (15,98). Other
anticoagulants (heparin, thrombin inhibitors) are also
unsuitable because these either interfere with the reac-
tivity of platelets or exclude the possibility of measuring
the generation or effect of thrombin.
. Use of a global stimulus:
Most PFTs in clinical use are aggregation based. It has
long been assumed that soluble agonists, generated byplatelets, initiate platelet aggregation and thrombus
growth. Assessment of thrombotic status on the basis of
platelet aggregation response to only 1 or 2 agonists
ignores the complexity of the mechanism of arterial
thrombus formation. Arterial thrombosis occurs at path-
ological high shear stresses (10,000 s1), which create
rapid and strong bonds between platelets without prior
activation (99,100). The release of soluble agonists
(thromboxane, ADP, thrombin) occurs secondary to
shear-induced platelet activation (101). Although the
IMPACT-R and PFA-100 are generally regarded as
“high shear–induced PFTs,” the shear rate in
IMPACT-R is only 1,800 s1(therefore, this test mea-
sures platelet adhesion but not aggregation) and in
PFA-100 is generously estimated at 5,000 to 6,000 s1.
Platelet interaction with von Willebrand factor, throm-
bin generation by shear-activated platelets, and shedding
of microparticles by shear-activated platelets (a major
contributor to thrombin generation) occur only at shear
rates exceeding 10,000 s1, and aggregates thus formed
are unstable until the shear rate is 20,000 s1 (may
reach 250,000 s1), such as that in the apex of a 70%
arterial stenosis (102,103).
3. Involvement of platelet-dependent thrombin generation:
Current PFTs do not take into account the procoagulant
activity of platelets, namely the significant contribut-
ion of platelets to coagulation through local thrombin
generation. Thrombin is the most potent platelet ago-
nist and, through fibrin formation, stabilizes the un-
stable platelet aggregates into a firm thrombus, capable
of causing lasting arterial occlusion. Aspirin dose-
dependently reduces thrombin generation with conse-
quent attenuation of thrombin-mediated coagulant reac-
tions (104). By inhibiting the P2Y12 receptor,
clopidogrel inhibits platelet-dependent thrombin gener-
ation (105). Further, current point-of-care PFTs most
frequently employ citrate-anticoagulated blood, and at
the very low plasma calcium levels therein, platelets do
not generate thrombin (17), and consequently, the effect
of thrombin on platelets is also attenuated (106).
. Clear definition of safety/efficacy thresholds and evalua-
tion of clinical usefulness:
In order to incorporate PFTs into routine use, PFTs
should have clearly defined normal ranges indicating
both the range for efficacy and the threshold for safety, in
various clinical settings. To be used for screening, any
PFT, like other biomarkers, should be evaluated for
clinical utility in terms of accuracy in identifying patients
at risk, the strength of its association with outcome, its
ability to discriminate between individuals at different
risk levels (C-value), and the incremental value it adds in
prognostic information over standard risk factors (107).
Cut values should be based on receiver-operating char-
acteristic curve analysis, but this is not enough (108,109).
The incremental value of PFT, over and above conven-
tional risk scoring, should be evaluated in terms of its
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index) value (107,109). Validation of PFT usefulness in
large prospective studies is required to confirm any
proof-of-concept findings. PFT should be undertaken
not only when practicable, but when it can discriminate
sensitively between high- and low-risk patients, can lead
to alterations in treatment that improve outcomes and is
cost effective (109). None of the PFTs discussed here
have been fully evaluated and validated to meet require-
ments for adoption for screening, according to the
criteria for novel biomarker evaluation recommended by
the American Heart Association (109).
. Quality control:
Quality assurance is as important for PFTs as for other
conventional laboratory-based tests (110) and is partic-
ularly pertinent, given the discrepancy in results between
studies using the same PFT. Reproducibility is a prereq-
uisite for successful use of a biomarker (109). Internal
quality control is required to assess the accuracy and
reproducibility of a test on an ongoing basis, and external
quality assessment to check agreement between one
laboratory’s results with those of others. Error is most
often pre-analytical (variable blood draw, collection,
blood/anticoagulant ratio, transportation, and storage)
but may also be analytical (calibration, reagent issues,
methodological or instrument problems), post-analytical,
and interpretative. Barriers to adoption of standardized
quality assurance for PFTs include: 1) the need for
frequent blood samples, both from many normal donors
and affected patients, which maybe practically, clinica-
lly, and ethically challenging; 2) time-delay issues, due
to transportation, or with tests employing non-
anticoagulated blood; and 3) clinicians, because many
near-patient PFTs are performed by clinicians with little
or no training in quality control, which may be accept-
able for some tests, such as the VerifyNow, where the
methodology is so simple as to render the chance of
erroneous result extremely unlikely, whereas complex test
procedures, such as whole-blood aggregometry and
LTA, have a much higher potential for analytical error
(110,111). There is no ideal external quality assurance,
although modified forms for PFTs have been proposed,
and uptake should be encouraged (110,112).
uture Directions and Clinical Considerations
FTs have the most to offer in detecting those who are at
ighest risk of future cardiovascular events. Importantly,
FT results will never be the sole determinant, but 1 of
ultiple contributors to cardiovascular risk. Many studies
sing PFTs have evaluated these tests in stable cardiovas-
ular disease, where event rates are low. In order to assess
he predictive benefit of these tests and to assess whether
ndividualization of antiplatelet therapy based on the results
f PFT will alter clinical outcome, large randomized clinical
rials should be performed in the highest-risk groups (such cs ACS patients with high GRACE [Global Registry of
cute Coronary Events] risk scores) so that these are
dequately powered to detect outcomes. Because of the low
ncidence of MACE and bleeding complications following
CI, assessment of the utility of PFTs requires evaluation in
ery large and costly clinical trials, to which there are
umerous barriers. Funding such trials is enormously ex-
ensive. Drug manufacturers may have little interest in
etecting persistent on-treatment platelet hyperreactivity.
evice manufacturers, however, are unlikely to be able to
und trials of sufficient magnitude. Furthermore, choice of
FT(s), timing of testing, and the ever-expanding arma-
entarium of antithrombotic medications coming online
re going to make the ideal trial nearly impossible to
erform.
The optimal timing of PFT is important, especially in
CS. Baseline assessment is often not possible before
nitiation of treatment, because many, especially those with
T-segment elevation myocardial infarction, will have re-
eived DAPT and often a thrombin inhibitor by the time of
resentation. Despite testing just before hospital discharge,
dministration of earlier anticoagulants may still distort
FT results. Assessing patients at 6 weeks follow-up to
uide therapy, after the acute inflammatory response has
ettled, has the obvious limitation that the first 4 to 6 weeks
fter an ACS is actually the highest thrombotic risk period.
hether a single result or whether serial testing is required
or ongoing therapy is also unclear.
It also unclear how PFT results might influence prescrib-
ng. In the acute setting, dosages can certainly be increased,
hich, with many agents, can improve PFT results, but
here are also many newer agents that reduce MACE in
igh-risk groups, such as ticagrelor and prasugrel, irrespec-
ive of PFT. In aspirin-resistant patients identified by LTA,
icagrelor achieved greater inhibition of platelet aggregation
han clopidogrel (113). Prasugrel is more effective than
lopidogrel in reducing platelet reactivity in healthy sub-
ects, as measured with aggregometry (114); in patients with
RPR on clopidogrel assessed with VerifyNow (74,115);
nd in stable CAD patients as measured by LTA; and
rasugrel lowers the proportion of pharmacodynamic non-
esponders compared with clopidogrel (116). Ticagrelor
roduces a significantly higher platelet inhibition compared
ith prasugrel, as measured with VerifyNow (93). However,
he clinical utility of switching drugs on the basis of PFT
esults in reducing adverse events could not be demonstrated
n stable CAD patients, perhaps due to the low event rate
fter PCI with contemporary DES in this setting (115).
hether it is clinically more (cost) effective to limit
rasugrel and ticagrelor to patients with HRPR, or
hether it is more efficacious to administer these drugs
or all licensed indications without performing PFT,
emains to be established.
Novel agents to prevent coronary thrombosis, targeting
hrombin-mediated pathways, are forthcoming. These in-
lude direct Xa inhibitors (apixaban, rivaroxaban, and dar-
2126 Gorog and Fuster JACC Vol. 61, No. 21, 2013
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PAR-1 antagonists (vorapaxar and atopaxar). Although
substantial review of these agents is beyond the scope of this
review, rivaroxaban appears to show the most promise in
ACS, reducing MACE without unacceptable increase in
bleeding (117). Atopaxar, evaluated only in a relatively small
trial, did not increase bleeding and shows a possible signal
for ischemic event reduction (118). Vorapaxar inhibits
thrombin receptor activating peptide (TRAP)-mediated
platelet aggregation as measured with LTA, in a dose- and
time-dependent manner (119). The effect of thrombin on
platelet aggregation may be measured with thromboelastog-
raphy by assessing the rapidity of fibrin–platelet clot forma-
tion, a marker of thrombin activity, and clot strength,
reflecting thrombin-induced fibrin–platelet interaction
(120,121). The role of PFT in assessing response to these
agents and guiding therapy remains to be established, but
results may be difficult to interpret due to the relative
contribution of thrombin generation by activated platelets to
the test results.
Conclusions
Despite having been in use for more than a decade, PFTs
have failed to realize the hopes they generated for clinical
practice. Identification of those at risk, who most require
antiplatelet medication, is still an urgent task. Unfortu-
nately, PFTs in current clinical use have very limited ability
to detect platelet hyperreactivity, a prothrombotic condition
in healthy subjects. Identification of antiplatelet nonrespon-
siveness is highly test specific, and does not allow individ-
ualization of antiplatelet therapy or identification of non-
compliance. The usefulness of PFTs in predicting MACE
after PCI is variable at best and often modest. Whether
PFTs have the ability to predict adverse cardiac events is
contentious. Although HRPR has been shown by some
studies to be associated with an increased risk of adverse
cardiac events, many studies show that PFTs, especially
point-of-care tests, cannot reliably discriminate between
patients with and without a primary endpoint during
follow-up. PFTs may be useful at a population level, but not
for the individual. Large clinical trials have not been
performed that demonstrate that altering treatment, on the
basis of PFT results, leads to an improvement in clinical
outcomes. None of the PFTs currently meet the criteria for
screening as a novel biomarker according to American
Heart Association criteria. Because the increased effective-
ness of novel antiplatelet drugs comes at a price of greater
bleeding, identification of such risk would be of paramount
importance. However, PFTs provide very limited prognos-
tic information on bleeding, and their value in this setting is
not established. Although finding a physiologically relevant
and clinically applicable PFT is more important than ever, a
critical reappraisal of present techniques in light of clinical
requirements is needed. Radical changes—such as the use of
native, instead of anticoagulated, blood; global stimulus, in-stead of several different agonists; involvement of platelet-
dependent thrombin generation in the test result; and identi-
fying a “safety window” for each antiplatelet drug, with
discriminatory and reclassification value of PFT established in
large-scale clinical trials—would be highly desirable.
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